Precipio, Inc. (PRPO)
| Market Cap | 56.63M |
| Revenue (ttm) | 24.05M |
| Net Income (ttm) | -363,000 |
| Shares Out | 1.78M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 88,882 |
| Open | 30.91 |
| Previous Close | 30.70 |
| Day's Range | 29.83 - 32.40 |
| 52-Week Range | 5.74 - 32.40 |
| Beta | 1.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 12, 2026 |
About PRPO
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut. [Read more]
Financial Performance
In 2025, Precipio's revenue was $24.05 million, an increase of 29.77% compared to the previous year's $18.53 million. Losses were -$363,000, -91.54% less than in 2024.
Financial StatementsNews
Precipio Earnings Call Transcript: Q4 2025
Achieved positive cash flow and 30% revenue growth in 2025, driven by Pathology Services and improved margins. Products Division poised for growth in 2026 with new commercial hires and scalable manufacturing, targeting a $500M addressable market.
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 20...
Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M
Precipio Takes Major Steps Toward a Clean Balance Sheet
Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstanding Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstanding
Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates clear, positive impacts on patient care Joint study conducted with Memorial Sloan Kettering Cancer Center demonstrates cl...
Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact
NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its ...
Precipio Announces its Q3-2025 Financial Results
Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter
Precipio Earnings Call Transcript: Q3 2025
Q3 2025 saw record revenue, first-ever positive adjusted EBITDA, and strong cash generation, driven by double-digit growth in both divisions and margin expansion. Strategic investments set the stage for continued growth and financial independence.
Precipio Announces Q3-2025 Shareholder Update Call
NEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2025 corporate update call on November 17th, 2025 at 5:00...
Precipio Announces its Q2-2025 Financial Results
NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its 10-Q report today.
Precipio Earnings Call Transcript: Q2 2025
Q2 2025 delivered strong revenue growth, improved margins, and progress toward break-even, with Pathology Services and Products Divisions both performing well. Strategic investments and a warrant conversion minimized dilution, while a robust customer pipeline supports continued momentum.
Precipio Announces Q2-2025 Shareholder Update Call
NEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 P...
Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless
NEW HAVEN, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with its largest warrant holder, amending the ex...
Precipio Announces its Q1-2025 Financial Results
NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its 10-Q report today.
Precipio Earnings Call Transcript: Q1 2025
Q1 2025 saw 43% year-over-year revenue growth, margin expansion, and improved cash use, despite seasonal headwinds. Regulatory wins and the resolution of FDA LDT uncertainty are expected to drive further growth, with positive cash flow anticipated by Q2 or Q3.
Precipio Announces Q1-2025 Shareholder Update Call
NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q1-2025 corporate update call on May 15th, 2025 at 5:00 P...
Precipio Earnings Call Transcript: Q4 2024
Q4 2024 saw nearly 26% revenue growth year-over-year, positive adjusted EBITDA, and positive cash flow, with the pathology division exceeding break-even and the product division maintaining a $700K run rate. Strategic focus for 2025 includes scaling growth and enhancing market visibility.
Precipio Announces Q4 and year-end 2024 Shareholder Update Call
NEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2...
Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)
Both metrics demonstrate the ability to achieve financial independence Both metrics demonstrate the ability to achieve financial independence
Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs
NEW HAVEN, Conn., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announced that options granted to senior management on January 14 would vest...
Precipio Announces Q3-2024 Shareholder Update Call
NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2024 corporate update call on November 18th at 5:00 PM ET...
Precipio Earnings Call Transcript: Q3 2024
Q3 2024 results show strong growth, with pathology revenues up 18% and products up 13% sequentially. Cash burn dropped 75% year-over-year, and break-even is within reach, eliminating the need for further capital raises.
Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping
The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients The unique assay enables laboratories to provide clinicians with more informed tre...
Precipio Announces Employee Stock Option Plan Repricing
NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company's repricing of a portion of its employee stock options ...
Precipio Announces Q2-2024 Shareholder Update Call
NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ...